SCHEMBL3596270

SCHEMBL3596270

CC1=CC(CNc2ccc(Cl)cc2)=CC(C)[CH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
RAB9A P51151 3/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
RECQL P46063 1/20 0.40
CNR2 P34972 1/20 0.38
NPC1 O15118 3/20 0.36
MAPT P10636 3/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP2D6 P10635 1/20 0.36
HPGD P15428 1/20 0.36
GFER P55789 1/20 0.36
LMNA P02545 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
HDAC1 Q13547 1/20 0.34
FFAR1 O14842 1/20 0.34
TP53 P04637 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4459326 0.75 RAPGEF4 (0.31)
SCHEMBL6416118 0.64 MEN1 (0.67) MEN1KMT2ARAB9ACYP1A2CYP2C9
SCHEMBL10669862 0.64 MEN1 (0.67) MEN1KMT2ARAB9ACYP1A2CYP2C9
SCHEMBL10945837 0.63 MEN1 (0.71) MEN1KMT2ARAB9ACYP1A2CYP2C9
SCHEMBL11512612 0.63 MEN1 (0.71) MEN1KMT2ARAB9ACYP1A2CYP2C9
SCHEMBL15497176 0.61 MEN1 (0.64) MEN1KMT2ARAB9ACYP1A2CYP2C9
SCHEMBL632439 0.61 CNR2 (0.48) MEN1KMT2ARAB9ACYP1A2CYP2C9
SCHEMBL11526668 0.60 MAPT (0.77) MEN1KMT2ARAB9ACYP1A2CYP2C9
SCHEMBL4190358 0.60
SCHEMBL9639726 0.60 MAPT (0.55) MEN1KMT2ARAB9ACYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100063044-A1 SUBSTITUTED ANILINE DERIVATIVES H. LUNDBECK A/S (DK) 2010-03-11 US disclosed
US-7601870-B2 Such as Hexanoic acid (4-bromo-2,6-dimethyl-phenyl)-amide; potassium channel modulators; epilepsy H. LUNDBECK A/S (DK) 2009-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063044-A1 SUBSTITUTED ANILINE DERIVATIVES NDUFS3, NAT1, PRMT3 MEN1 1540/4885KMT2A 398/4885RAB9A 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.